Author: Leigh MacMillan
Byndloss selected for Burroughs Wellcome Fund infectious disease award
Jun. 7, 2023—Vanderbilt's Mariana Byndloss, DVM, PhD, is one of eight Burroughs Wellcome Fund 2023 Investigators in the Pathogenesis of Infectious Disease.
Neurofluid flow and Alzheimer’s disease
May. 22, 2023—Vanderbilt researchers used novel MRI methods to noninvasively quantify measures of neurofluid circulation and found that hypertrophy of a site of cerebrospinal fluid egress may be related to amyloid-beta retention in Alzheimer’s disease.
A critical skin enzyme
May. 18, 2023—Detailed studies of the enzymatic properties of PNPLA1 support the requirement for this protein in skin barrier formation.
Neural networks probe proteins
May. 9, 2023—A machine learning method based on neural networks outperformed a mutational scanning model at identifying disease-causing mutations in an Alzheimer’s disease protein, suggesting the method could be useful for facilitating therapeutic design.
Diabetes drugs associated with fewer adverse cardiac events in older veterans: study
May. 8, 2023—Vanderbilt research finds that GLP1 receptor agonists — a class of diabetes medications — are associated with fewer major adverse cardiovascular events than another type of diabetes drug (DPP4 inhibitors) in older veterans with no prior heart disease.
Improved imaging for kidney disease
May. 8, 2023—Vanderbilt researchers identified optimal MRI parameters for estimating the severity of polycystic kidney disease, a common inherited disorder that can lead to end-stage renal failure.
Tracking lung macrophages
May. 4, 2023—A new technique will allow researchers to track subsets of immune cells that patrol and defend the lungs, to better understand the roles of these cells during lung inflammation, infection and injury.
COVID alters respiratory microbiota
Apr. 25, 2023—COVID-19 infection alters the microbes of the upper respiratory tract for at least several weeks, and such disturbances could impact disease severity and be targets for therapeutic interventions.
Novel drugs have potential for treating tuberculosis
Apr. 24, 2023—Drug-resistant tuberculosis is on the rise, and novel antibacterial drugs called SPTs have potential for treating the deadly lung infection.
Study details RNA editing in virus-infected cancer cells
Apr. 20, 2023—Vanderbilt researchers detail the landscape of RNA editing — a form of RNA modification — in primary effusion lymphoma cells during Kaposi’s sarcoma-associated herpesvirus infection and identify an edited viral microRNA that is critical for infection.
Ovarian cancer expert Odunsi to deliver next Discovery Lecture
Mar. 30, 2023—Kunle Odunsi, MD, PhD, director of the University of Chicago Comprehensive Cancer Center, will deliver the next Discovery Lecture at Vanderbilt on Thursday, April 6.
VUMC researcher selected for Global Scholars Program
Mar. 30, 2023—Vanderbilt researcher P. Brent Ferrell, MD, is leading one of five projects selected by the 2022 Novartis Institutes for BioMedical Research Global Scholars Program.
